Wells Fargo & Company Increases Medline (NASDAQ:MDLN) Price Target to $47.00

Medline (NASDAQ:MDLN) had its target price raised by investment analysts at Wells Fargo & Company from $42.00 to $47.00 in a report released on Friday,Benzinga reports. The firm presently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price objective would suggest a potential downside of 2.83% from the stock’s previous close.

A number of other equities research analysts also recently issued reports on MDLN. Stifel Nicolaus set a $55.00 price target on Medline in a research note on Wednesday. UBS Group boosted their price objective on shares of Medline from $48.00 to $57.00 and gave the company a “buy” rating in a research report on Thursday. Sanford C. Bernstein assumed coverage on Medline in a report on Monday, January 12th. They issued an “outperform” rating and a $49.00 target price on the stock. Zacks Research upgraded Medline to a “hold” rating in a research report on Tuesday, January 13th. Finally, Truist Financial began coverage on Medline in a research report on Monday, January 12th. They issued a “buy” rating and a $52.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $50.35.

Medline Trading Down 1.1%

NASDAQ:MDLN traded down $0.52 during trading hours on Friday, reaching $48.37. The company had a trading volume of 844,446 shares, compared to its average volume of 3,304,363. The company’s 50 day simple moving average is $44.40. Medline has a 52 week low of $34.89 and a 52 week high of $50.88.

Medline (NASDAQ:MDLN) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.24 by ($0.25). The firm had revenue of $7.79 billion during the quarter, compared to analysts’ expectations of $7.52 billion. The company’s revenue was up 14.8% compared to the same quarter last year.

Insider Buying and Selling

In other Medline news, Director Charles N. Mills purchased 2,579,310 shares of the company’s stock in a transaction on Thursday, December 18th. The stock was acquired at an average cost of $29.00 per share, for a total transaction of $74,799,990.00. Following the purchase, the director directly owned 2,441,379 shares of the company’s stock, valued at $70,799,991. This trade represents a -1,870.00% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Andrew J. Mills acquired 2,586,206 shares of the business’s stock in a transaction on Thursday, December 18th. The shares were bought at an average cost of $29.00 per share, with a total value of $74,999,974.00. Following the completion of the acquisition, the director owned 2,586,206 shares in the company, valued at approximately $74,999,974. This represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information.

Institutional Investors Weigh In On Medline

Several large investors have recently made changes to their positions in MDLN. Sound Income Strategies LLC bought a new position in Medline during the fourth quarter valued at approximately $25,000. Entrust Financial LLC purchased a new stake in shares of Medline during the 4th quarter worth approximately $26,000. NBC Securities Inc. bought a new position in shares of Medline during the 4th quarter valued at approximately $28,000. Global Retirement Partners LLC bought a new stake in Medline in the fourth quarter worth $31,000. Finally, North Star Investment Management Corp. purchased a new stake in Medline during the fourth quarter valued at $36,000.

Medline News Summary

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Multiple brokerages raised price targets and turned more constructive after the quarter — Citi raised its target to $60 (buy), UBS to $57 (buy), BMO to $54 (outperform) and RBC to $53 (outperform), signaling analyst confidence in Medline’s growth outlook. Analysts Boost Their Forecasts Following Q4 Results
• Positive Sentiment: Revenue beat: Q4 sales were $7.79B vs. consensus ~$7.52B, up ~14.8% year-over-year — supports top-line momentum and was called “record sales” in earnings highlights. Q4 2025 Earnings Call Highlights
• Neutral Sentiment: The full Q4 earnings call transcript and company commentary are available for detail on margins, margin drivers and capital/ESOP plans — useful for assessing whether the EPS miss is one-off or structural. Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Independent coverage provides quick snapshots of results and context on product/segment performance — use these to cross-check management’s narrative. Q4 Earnings Snapshot
• Negative Sentiment: EPS miss: reported EPS was ($0.01) vs. consensus $0.24 — the earnings shortfall is the primary near-term negative catalyst and was cited as the reason for the share gap down. Shares Gap Down Following Weak Earnings
• Negative Sentiment: IPO/ESOP scrutiny: the company’s public filing and ESOP plans are under increased public scrutiny, raising questions about governance, dilution and guidance clarity as Medline transitions to the public market. IPO Opens Public Scrutiny On Growth Guidance And ESOP Plans
• Negative Sentiment: Coverage noting “shortcomings”: some write-ups highlight that, despite growth, the quarter revealed weaknesses (profitability/mix) that need addressing — a reminder that revenue strength hasn’t fully translated into EPS beat. Reports Growth Despite Earnings Shortcomings

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.